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Abstract: Chemical allergy is of considerable importance to the toxicologist, who, amongst other things,
has the responsibility of identifying and characterizing the skin (and respiratory) sensitizing potential
of chemicals, and estimating the risk they pose to human health. Allergic contact dermatitis (ACD)
is to a large extent a preventable disease. Although quantitative risk assessment (QRA) for contact
allergy can be performed, it is reasonable to ask why the burden of the skin disease ACD appears to
remain stubbornly high, and in particular, that the general level of ACD to sensitizing ingredients
found in cosmetics has not fallen noticeably over recent decades; some could argue that it has increased.
In this review, this conundrum is addressed, considering whether and to what extent the prevalence of
cosmetic allergy is truly unchanged, whether the predicted test methods and potency estimations are
sufficiently precise and how proposed changes to the QRA process (i.e., cumulative exposure) may
ameliorate the situation. Improved and more widespread use of risk assessment, better education of
risk assessors, better post-marketing surveillance and monitoring of dermatology clinic feedback to
improve QRA, all together could help to “make contact allergy history”.
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1. Introduction
At the core of toxicology lies the underlying premise that it is the dose that makes the poison, the
original concept being attributed to Paracelsus or Philippus Aureolus Theophrastus Bombastus von
Hohenheim [1]. This is certainly the case for skin sensitizing chemicals which have the capacity to
induce contact allergy in humans and thereby lead to the disease allergic contact dermatitis (ACD)—the
existence of dose–response relationships and the existence of thresholds has long been recognized [2–4].
Furthermore, it is true for this toxicology endpoint that the simple paradigm “risk = hazard ˆ exposure”
must apply. It is also important to recognize that skin sensitizers vary widely in their relative potency, with
the consequence that the paradigms might better be represented as “risk = hazard (potency) ˆ exposure”.
Against this background must be set the reality that in vivo methods for the predictive identification
of skin sensitizers have been available for many decades [5,6]. These methods are rightly regarded
as generally predictive of human hazard [7,8] and for approaching 20 years, the lead method, the
local lymph node assay (LLNA) has also delivered information on the relative potency of identified
skin sensitizers [9–13]. This information has been combined with information on human exposure in
a process termed quantitative risk assessment (QRA) [14–17]. Given this background therefore it is
reasonable to ask why the burden of the skin disease ACD appears to remain stubbornly high, and in
particular, that the level of ACD to sensitizing ingredients found in cosmetics has not fallen noticeably
over recent decades. In the material which follows, this conundrum is addressed, considering whether
and to what extent the prevalence of cosmetic allergy is truly unchanged, whether the predictive test
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methods and potency estimations are sufficiently precise and how proposed changes to the QRA
process, in particular the estimation of aggregate exposure to sensitizing materials, has the ability
to transform the situation. Finally, attention is given to the importance of monitoring the impact of
improvements to risk assessment and risk management via the day-to-day assessment of contact
allergy undertaken by dermatologists performing diagnostic patch testing in their clinics [18].
2. Allergic Contact Dermatitis to Cosmetic Ingredients
Other contributors to this Special Issue of the journal will provide much greater detail on the topic
of those ingredients in cosmetics which are most commonly associated with the causation of contact
allergy and ACD, so these will not be reiterated here. However, it is important that we exemplify how
the frequency of contact allergy to a range of cosmetic ingredients has been documented over a period
of many years. In addition, it is also of note that the diagnostic patch testing series used to evaluate
potential cosmetic allergy, while not entirely static, has not changed over perhaps half a century of
patch testing history to such a degree that it is no longer recognizable. Both of these are generally
consistent with the view that contact allergy to cosmetic ingredients is a continuing problem.
Perhaps it is most appropriate to start with the last mentioned point: the standard series for
diagnostic patch testing has been in place for at least four decades. The initial and the current patch
testing series are displayed in Table 1. There is considerable overlap, although perhaps only a few
(sequence numbers 2, 9, 11, 14, 16 and 18) are specifically relevant for cosmetics. Notably, of the
additional eight in the 2015 series, 75% (sequence numbers 21, 22, 25, 26, 27 and 28) are relevant to
cosmetics, which of itself is suggestive of an increasing and/or increasingly understood, rather than
a decreasing, problem. At the time of writing in December 2015, the additional cosmetic series from
one supplier contains a further 57 patch test allergens. Some might well argue that such a substantial
list is hardly consistent with a fully successful cosmetics risk assessment process.
Table 1. Standard Series in 1974 versus 2015.
No. ICDRG 1974 1 European Baseline Series 2015
1 Potassium dichromate Potassium dichromate
2 p-Phenylenediamine p-Phenylenediamine
3 Thiuram mix Thiuram mix
4 Neomycin sulphate Neomycin sulphate
5 Cobalt chloride Cobalt chloride
6 None Benzocaine
7 Nickel sulphate Nickel sulphate
8 Clioquinol Clioquinol
9 Colophony Colophony
10 Paraben mix Paraben mix
11 Black rubber mix N-Isopropyl-N’-phenyl-p-phenylenediamine
12 Wool alcohols (lanolin) Wool alcohols (lanolin)
13 Mercapto mix Mercapto mix
14 Epoxy resin Epoxy resin
15 Balsam of Peru (Myroxylon pereirae) Balsam of Peru (Myroxylon pereirae)
16 Carba mix Butyl phenolformaldehyde resin
17 Ethylenediamine HCl Mercaptobenzothiazole
18 Formaldehyde Formaldehyde
19 Fragrance mix 1 Fragrance mix I
20 Wood tars Sesquiterpene lactone mix
21 Naphthyl mix Quaternium-15
22 None 2-Methoxy-6-n-pentyl-4-benzoquinone
23 None Methylchloroisothiazolinone/methylisothiazolinone (MCI/MI)
24 None Budesonide
25 None Tixocortol pivalate
26 None Methyldibromo glutaronitrile (MDGN)
27 None Fragrance mix II
28 None Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC)
29 None Methylisothiazolinone
30 None Textile dye mix
1 The original numbering of the 1974 series has been modified slightly to facilitate comparison with the current
2015 series.
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As noted elsewhere in this issue, fragrances, hair dyes and preservatives are the most common
skin sensitizing chemicals associated with the induction of contact allergy and the causation of ACD
to cosmetic products [19]. Consequently, they provide useful markers for the prevalence of cosmetic
allergy, since several of these have been tested routinely over a few decades. For example, the North
American Contact Dermatitis Group (NACDG) has been reporting collated diagnostic patch test results
for many years [20–25]. From this can be abstracted information such as that shown in Figure 1,
which displays the overall incidence of contact allergy to three preservatives, the standard fragrance
mix (FM1) and the main sensitizing hair dye ingredient, p-phenylenediamine (PPD). Each of these
five contact allergy markers, all used in cosmetics, show variation over the approximately quarter
century period covered, but they do not indicate any general downward trend. It might be reasonable
to expect that since the QRA approach was developed specifically to assist with the high level of
fragrance allergy, then this source of contact allergy should be on the decline. However, the prevalence
of contact allergy to FM1 remained about 11% ˘ 2% over the testing period shown.
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Figure 1. Contact allergy to markers of cosmetic allergy over the 25 years in the USA. 
The experience from North America can readily be reproduced using dermatology clinic data 
from Europe. For example, a 17 year study in the UK showed a steady rate of approximately 8% ± 2% 
positive to FM1 for the period up to 1996 [26]. Similarly, over a 21 year period, until 2011, a 
frequency of 9.1% positive to FM1 was reported from Belgium [27]. These latter authors further 
demonstrated that for most of the eight ingredients of FM1, despite some fluctuations, displayed no 
significant downward trend. Lastly, the latest results from the German group report a modest 
increase in the prevalence of contact allergy to FM1, with a rise to 9.6% positive [28]. Other regions of 
the world report even higher prevalence values, for example in Thailand a steady rate of just over 
17% positive to FM1 was reported over a 10 year period to 2008 [29]. 
3. Hazard Identification and Characterization 
In vivo methods for the predictive hazard identification of skin sensitizing chemicals have been 
available for decades [5,6]. Large databases of results have been published [30–33]. This body of 
work demonstrated that the great majority of all except the weakest human skin sensitizers could be 
identified, suggesting that their potential for causing adverse human health effects could be assessed 
and managed. However, in response to animal welfare (and other methodological) concerns, the 
murine LLNA was developed and this also permitted the relative potency of skin sensitizers to be 
measured as the EC3 value [9]. This was seen as a critical step forward in terms of hazard 
characterization [11]. Obviously, this would not be a meaningful advance if relative potency in the 
mouse did not reflect the situation in humans. Fortunately, a series of comparative studies provided 
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The experience from North America can readily be reproduced using dermatology clinic data
from Europe. For example, a 17 year study in the UK showed a steady rate of approximately 8% ˘ 2%
positive to FM1 for the period up to 1996 [26]. Similarly, over a 21 year period, until 2011, a frequency
of 9.1% positive to FM1 was reported from Belgium [27]. These latter authors further demonstrated
that for most of the eight ingredients of FM1, despite some fluctuations, displayed no significant
downward trend. Lastly, the latest results from the German group report a modest increase in the
prevalence of contact allergy to FM1, with a rise to 9.6% positive [28]. Other regions of the world report
even higher prevalence values, for example in Thailand a steady rate of just over 17% positive to FM1
was reported over a 10 year period to 2008 [29].
. Hazard Identification and Characterization
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characterization [11]. Obviously, this would not be a meaningful advance if relative potency in the
mouse did not reflect the situation in humans. Fortunately, a series of comparative studies provided
reassurance in this respect [12,13,34–37]; most recently, a series of approximately 130 substances have
been characterized according to their relative human potency using, only human data, to provide
an essential basis for comparative studies [38]. Despite this work, there remains a degree of uncertainty:
the LLNA potency predictions are a valuable indicator, but like any aspect of predictive toxicology,
they are not perfect. For example, some salicylates were over-predicted, whereas an aldehyde was
under-predicted [13]. Furthermore, even a cursory examination of published correlations between
LLNA EC3 values and skin sensitization thresholds in the human repeated insult patch test (HRIPT)
indicates that despite a clear relationship, the “error bars” are wide (e.g., [37]). Of course, much of this
uncertainty mainly derives from the poor quality of the human, not the toxicological, data.
The new reality for cosmetic ingredients and products is that the potential for skin sensitization
must be determined without the use of animal methods. It is for this reason that several non-animal
methods have been developed, validated and now appear either in OECD Guidelines or are progressing
towards that endpoint (reviewed in [39]). It is not necessary here to review the detail of these methods,
or how they may be used in combination to identify skin sensitization hazards as that has been reported
and discussed extensively elsewhere [40–46]. What is clear from this is that two points emerge. Firstly,
a degree of consensus is building that adoption of the majority conclusion from a combination of up to
three in vitro assays representing the first three key events of the skin sensitization adverse outcome
pathway is sufficient for hazard identification [43]. Secondly, it is recognized that this approach does
not inform on the relative potency of skin sensitizers, such that an alternative strategy is required,
around which there is a discussion of possibilities, but no degree of consensus has been reached, and
today it is hardly possible to say if one strategy is better than the other. Examples of the latter can be
found in several publications [43–47]. Potency might be estimated through Quantitative Mechanistic
Modeling or alternatively through the application of Bayesian statistical approaches, the latter having
given promising results for the prediction of four sensitizer potency classes, but not yet to predict
a complete dose–response profile or EC3 values which remains a challenge [44,46]. Most of these efforts
have been focused on the prediction of LLNA potency classes, since that is where the largest datasets of
relative potency information can be found. However, the ultimate goal is prediction of relative potency
in humans, not the mouse, so calibration of any approach really should be directed towards human
data, such as that published recently [38]. In that work, six human potency categories were detailed.
For practical purposes, each of these could (and should) be associated with a default NESIL value (the
induction threshold adopted as the starting point for skin sensitization QRA). By focusing non-animal
approaches on the prediction of a human potency category, much of the uncertainty associated with
LLNA EC3 values and the extrapolation from mouse to humans could be eliminated. Further work is
necessary, which is likely to require a better understanding of the driving forces responsible for in vivo
potency before an effective in vitro strategy can be put in place [48].
4. Risk Assessment/Management
Current mechanistic understanding of allergy is such that it can be assumed that the development
of sensitization (and also the elicitation phase) is a threshold phenomenon at both the individual and
the population level. Prevention of sensitization in naive individuals, rather than elicitation in already
sensitized persons, is a more suitable and health protective health endpoint. For those who are already
allergic, allergen avoidance, assisted by proper product labeling is the only certain way to prevent the
expression of allergic skin reactions.
The challenge is to identify levels of exposure below which sensitization will not be acquired.
It has already been noted that the development of skin sensitization QRA offers the best method for
determining human safety, that argument being based on a combination of long-standing and well
founded toxicology approaches and supported by a substantial body of scientific understanding [14–16].
Evidence concerning the validity of this strategy has been presented [49]; many publications document
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its application (e.g., [38,50–53]); situations where outbreaks of ACD have occurred further serve to
demonstrate that failure to use QRA, or at least to use it properly, leads to problems (e.g., [54–56]).
In addition, scrutiny of QRA and its scientific basis has continued, leading to proposals for refinement
of the approach [57,58]. In the second half of 2015, this led to an updated version of QRA (termed
QRA2.0) being presented to the European Commission for independent review.
Notwithstanding the above, the aim of risk assessment and risk management is to limit human
exposure to skin sensitizing substances such that the induction of contact allergy is either eliminated,
or reduced to an acceptable level. Where contact allergy in a population has not been controlled, then
the aim shifts to limitation of the likelihood of the elicitation of ACD (e.g., [59,60]). Consequently,
perhaps the real success embedded in QRA2.0 is the incorporation of aggregated exposure, a key
contrast with the original QRA in which only the use of a skin sensitizer in single product situations
was evaluated.
5. Summary
Ultimately, the real proof that skin sensitization QRA works can be derived only from human
experience. In turn, that experience comes from not from the absence of evidence (e.g., cosmetovigilance),
but from the active assessment of contact allergy [18,61]. Currently, and as detailed at the beginning of
this article, that assessment shows that cosmetic allergy is significant in degree and is not falling (see
Figure 1). QRA may well work in theory and the addition of aggregate exposure in QRA2.0 will improve
matters, but formal assessment can only be meaningful if its use is widespread and consistent. The most
probable area for that activity is fragrance allergy, where exposure from cosmetics dominates and
the industry develops QRA-based guidelines, which are adopted and applied globally. This will also
require a better training of risk assessors to make cosmetic contact allergy truly a subject of historical,
rather than current, interest.
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